Mydecine files a detailed patent application covering "multiple families of psilocin analogs."
Mydecine files a detailed patent application covering "multiple families of psilocin analogs."
GH Research reports its Q3 for 2021 and announces VERY successful results from its Phase 2a trial for Treatment Resistant Depression (TRD).
Novamind's new Salt Lake City clinic will specialize in treating substance abuse disorders.
Delic Holding Corp's subsidiary, Ketamine Wellness Centers, is planning to open two new clinics, in Salt Lake City, Utah
Novamind expands its treatment footprint via a new partnership with Uruguay-based Bienstar Wellness.
Compass Pathways provides further details on its Phase IIb results for the treatment of Treatment Resistant Depression, including reporting of additional "patient improvements".
UK-based Albert Labs receives conditional approval from the Canadian Securities Exchange (CSE) to commence trading under the symbol "ABRT". Trading expected to commence in early 2022.
Cybin seeks FDA approval for a new Phase 2 clinical trial aimed at treating "distress" among frontline healthcare practitioners.
atai Life Sciences adds to its holding in Compass Pathways, raising its ownership interest back to 20.8%.
Red Light Holland reports its results for Q2 fiscal 2021. - Quarterly revenues up to CAD$485,738 - A 64% increase in gross profit - 56% increase in the number of retail outlets selling TRIP products
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now